This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Optimer Soars on Antibiotic Data

Stocks in this article: OPTR VPHM GENZ

According to the top-line results from the phase III study announced Monday night, 88% of patients treated with OPT-80 achieved a clinical cure compared to 86% of patients treated with Vancocin.

Patients were treated with OPT-80 twice daily for 10 days. Vancocin was dosed four times daily, also for 10 days. A clinical cure was defined as patients requiring no further therapy for C. diff two days after completing treatment.

A key secondary endpoint of the study measured the recurrence, or relapse rate. Here, too, OPT-80 excelled, with just 15% of patients reporting a recurrence of the C. diff infection four weeks after treatment compared to a 25% recurrence rate reported for patients treated with Vancocin.

Optimer's phase III study was designed to show statistically non-inferior efficacy of OPT-80 compared to Vancocin on both the primary endpoint (cure rate) and the secondary endpoint of recurrence rate. The fact that OPT-80 was numerically superior on both endpoints is a big win for the drug.

Recurrence of C. diff infection in treated patients is a growing problem, so the lower recurrence rate for OPT-80 makes a strong case for using the drug as a first-line treatment.

A second phase III study of OPT-80 in C. diff patients is ongoing with data expected in the second half of 2009. Optimer also said it plans to resurrect partnering discussions for OPT-80. In 2007, an experimental antibiotic from Genzyme (GENZ) failed a closely watched phase III study.

Optimer shares closed Monday at $4.60 prior to the release of the OPT-80 study results. That news sent the stock up 90% to $8.75 in the after-hours session.

Know What You Own: In Tuesday's early trading, other top biotech performers include Genetic Technologies (GENE), Targacept (TRGT), Cytokinetics (CYTK) and BioDelivery Sciences (BDSI).

At the time of publication, Feuerstein's Biotech Select model portfolio was long Optimer Pharmaceuticals.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs